Schmid P, et al. - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer. ESMO Congress 2019, abstract LBA8_PR.
Gestage groei aantal patiënten met kanker in Nederland
feb 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie